1 Bergqvist D. Postoperative thromboembolism: frequency, etiology, prophylaxis. Berlin: Springer-Verlag; 1983. [section 1.1] [section 1.2] [section 2] [section 3.1] [section 3.2.1] [section 4.1] [section 4.2.1] [section 6]

2 Collins R, Scrimgeour A, Yusuf S, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomised trials in general, orthopedic and urologic surgery. N Engl J Med 1988; 318: 1162-73. [section 1.1] [section 1.3] [section 3] [table 5] [section 3.4.2] [section 4.1] [section 4.2.1] [section 4.2.2] [section 4.4] [section 6]

3 Collaborative overviews of randomised trials of antiplatelet therapy-III. Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. Antiplatelet Trialists' Collaboration. BMJ 1994; 308: 235-46. [section 1.1] [section 1.3] [table 2] [section 3.3.1] [table 3] [table4] [section 4.1] [section 4.4] [section 8]

4 Collins R, Baigent C, Sandercock P, Peto RO. Antiplatelet therapy for thromboprophylaxis: the need for careful consideration of the evidence from randomised trials. Antiplatelet Trialists' Collaboration. BMJ 1994; 309: 1215-7. [section 1.1] [section 1.3] [section 3] [table 3] [table4] [section 4]

5 Mismetti P, Laporte-Simitsidis S, Tardy B, Cucherat M, Buchmuller A, Juillard-Delsart D, et al. Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials. Thromb Haemost 2000; 83: 14-9. [section 1.1] [section 1.3] [section 3] [section 8] [section 8.2.4] [section 8.3] [section 8.3.1]

6 Scottish Intercollegiate Guidelines Network (SIGN). Antithrombotic therapy. Edinburgh: SIGN; 1999. (SIGN publication no. 36). [cited 5 Sep 2002]. Available from url: http://www.sign.ac.uk/guidelines/fulltext/36/index.html [section 1.1] [section 1.2] [section 1.3] [section 3.3.2] [section 3.3.3] [table 4] [section 3.4.4] [section 3.8] [section 6.3] [section 6.4.1] [section 7] [section 8.1.1] [section 8.1.2] [section 8.4] [section 13.3]

7 Sandler DA, Martin JF. Autopsy proven pulmonary embolism in hospital patients: are we detecting enough deep vein thrombosis? J R Soc Med 1989; 82: 203-5. [section 1.1] [section 1.2] [section 1.3] [section 8]

8 Gillies TE, Ruckley CV, Nixon SJ. Still missing the boat with fatal pulmonary embolism. Br J Surg 1996; 83: 1394-5. [section 1.1] [section 1.3]

9 Scottish Audit of Surgical Mortality. Annual Report 1998. Glasgow: Royal College of Physicians and Surgeons; 1998.

10 Campling EA, Devlin HB, Hoile RW, Lunn JN. The report of the National Confidential Enquiry into Perioperative Deaths, 1992/1993. London: National Confidential Enquiry into Perioperative Deaths; 1995.

11 Department of Health. Why mothers die: report on confidential enquiries into maternal deaths in the United Kingdom, 1994-1996. London: The Stationery Office; 1998.

12 Karwinski B, Svendsen E. Comparison of clinical and postmortem diagnosis of pulmonary embolism. J Clin Pathol 1989; 42: 135-9. [section 1.1] [section 1.3] [section 8] [section 8.3]

13 Baglin TP, White K, Charles A. Fatal pulmonary embolism in hospitalised medical patients. J Clin Pathol 1997; 50: 609-10. [section 1] [section 8] [section 8.3]

14 Leizorovicz A. Long-term consequences of deep vein thrombosis. Haemostasis 1998; 28 Suppl 3: 1-7.

15 Browse NL, Burnand KG, Thomas ML. Diseases of the veins: pathology, diagnosis and treatment. London: Edward Arnold; 1988. [section 1.1] [section 1.3] [section 2] [section 3]

16 Bergqvist D, Jendteg S, Johansen L, Persson U, Odegaard K. Cost of long-term complications of deep venous thrombosis of the lower extremities: an analysis of a defined patient population in Sweden. Ann Intern Med 1997; 126: 454-7.

17 Prandoni P, Lensing AW, Cogo A, Cuppini S, Villalta S, Carta M, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996; 125: 1-7. [section 1] [section 2]

18 Franzeck UK, Schalch I, Jager KA, Schneider E, Grimm J, Bollinger A. Prospective 12-year follow-up study of clinical and hemodynamic sequelae after deep vein thrombosis in low-risk patients (Zurich study). Circulation 1996; 93: 74-9. [section 1.1] [section 1.2]

19 Geerts WH, Heit JA, Clagett GP, Pineo GF, Colwell CW, Anderson FA Jr, et al. Prevention of venous thromboembolism. Chest 2001; 119 Suppl 1: 132-75. [section 1.2] [section 1.3] [section 1.6] [section 3.2.1] [section 3.2.3] [section 3.8] [section 3.9] [section 4.1] [section 4.3.2] [section 4.5] [section 5.1] [section 5.1.3] [section 5.1.4] [section 5.2.4] [section 5.4] [section 6.1.1] [section 6.2] [section 8]

20 Nicolaides AN, Arcelus J, Belcaro G, Bergqvist D, Borris LC, Buller HR, et al Prevention of venous thromboembolism. European Consensus Statement, 1-5 November 1991, developed at Oakley Court Hotel, Windsor, UK. Int Angiol 1992; 11: 151-9. [section 1] [section 3.2.1] [section 3.2.3] [section 3.8] [section 4] [section 5] [section 6.1.1] [section 6.2] [section 6.4.1]

21 Risk of and prophylaxis for venous thromboembolism in hospital patients. Thromboembolic Risk Factors (THRIFT) Consensus Group. BMJ 1992; 305: 567-74.

22 Scottish Intercollegiate Guidelines Network (SIGN). Prophylaxis of venous thromboembolism. Edinburgh: SIGN; 1995. (SIGN publication no.1). [section 1.2] [section 1.3] [section 1.4] [section 5]

23 Donaldson GA, Williams C, Scannell JG, Shaw RS. A reappraisal of the application of the Trendelenburg operation to massive fatal embolism. N Engl J Med 1963; 268: 171-4.

24 Dalen JE, Alpert JS. Natural history of pulmonary embolism. Prog Cardiovasc Dis 1975; 17: 259-70.

25 Perez JV, Warwick DJ, Case CP, Bannister GC. Death after proximal femoral fracture - an autopsy study. Injury 1995; 26: 237-40. [section 1] [section 5]

26 Walker AE, Campbell SE, Grimshaw JM, Tempest Study Group. Implementation of a national guideline on prophylaxis of venous thromboembolism: a survey of acute services in Scotland. Health Bull (Edinb) 1999; 57: 141-7. [section 1] [section 13.1] [section 13.2]

27 McEleny P, Bowie P, Robins JB, Brown RC. Getting a validated guideline into local practice: implementation and audit of the SIGN guideline in the prevention of deep vein thrombosis in a district general hospital. Scott Med J 1998; 43: 23-5. [section 1] [section 3.8] [section 3.9] [section 13.1]

28 Kelly B, Wales A, Wilson B, Jackson B, Leiberman DP, Lowe GD. Getting research evidence into practice. Health Bull (Edinb) 2001; 59: 57-9. [section 1] [section 3] [section 13.1]

29 Campbell SE, Walke AE, Grimshaw JM, Campbell MK, Lowe GD, Harper D, et al. The prevalence of prophylaxis for deep vein thrombosis in acute hospital trusts. Int J Qual Health Care 2001; 13: 309-16. [section 1] [section 3] [section 13.1] [section 13.2] [section 13.3]

30 Kakkar VV, Corrigan TP, Fossard DP, Sutherland I, Thirwell J. Prevention of fatal postoperative pulmonary embolism by low doses of heparin. Reappraisal of results of international multicentre trial. Lancet 1977; 1: 567-9. [section 1] [section 3.4.1] [section 3.4.2] [section 3.4.4] [section 4.1] [section 4.2.1]

31 Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet 2000; 355: 1295-302. [section 1] [section 3.3.1] [section 3.3.3] [table 3] [table4] [section 4] [section 5.1.2] [section 5.1.3] [section 5.2] [section 5.2.1] [section 5.2.2] [section 5.2.3] [section 5.4] [section 8]

32 Seagroatt V, Tan HS, Goldacre M, Bulstrode C, Nugent I, Gill L. Elective total hip replacement: incidence, emergency readmission rate, and postoperative mortality. BMJ 1991; 303: 1431-5.

33 Khaw FM, Moran CG, Pinder IM, Smith SR. The incidence of fatal pulmonary embolism after knee replacement with no prophylactic anticoagulation. J Bone Joint Surg Br 1993; 75; 940-1. [section 1] [table 5]

34 Warwick D, Williams MH, Bannister GC. Death and thromboembolic disease after total hip replacement. A series of 1162 cases with no routine chemical prophylaxis. J Bone Joint Surg 1995; 77: 6-10. [section 1] [section 5]

35 Murray DW, Carr AJ, Bulstrode CJ. Pharmacological thromboprophylaxis and total hip replacement. J Bone Joint Surg 1995; 77: 3-5.

36 Dunsmuir RA, Allan DB, Davidson LA. Early post-operative mortality following primary total hip replacement. J R Coll Surg Edinb 1996; 41: 185-7.

37 McGrath D, Dennyson WG, Rolland M. Death rate from pulmonary embolism following joint replacement surgery. J R Coll Surg Edinb 1996; 41: 265-6.

38 Murray DW, Britton AR, Bulstrode CJ. Thromboprophylaxis and death after total hip replacement. J Bone Joint Surg Br 1996; 78: 863-70.

39 Fender D, Harper WM, Thompson JR, Gregg PJ. Mortality and fatal pulmonary embolism after primary total hip replacement. Results from a regional hip register. J Bone Joint Surg Br 1997; 79: 896-9. [section 1] [section 5]

40 Lumpkin MM. FDA public health advisory. Anesthesiology 1998; 88: 27A-8A. [section 1] [section 7]

41 Wysowski DK, Talarico L, Bacsanyi J, Botstein P. Spinal and epidural hematoma and low-molecular-weight heparin. N Engl J Med 1998; 338: 1774-5. [section 1] [section 7]

42 Checketts MR, Wildsmith JA. Central nerve block and thromboprophylaxis - is there a problem? Br J Anaesth 1999; 82: 164-7.

43 Collins R, MacMahon S, Flather M, Baigent C, Remvig L, Mortensen S, et al. Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials. BMJ 1996; 313: 652-9. [section 1] [section 8] [section 8.1] [section 8.1.2]

44 The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group. Lancet 1997; 349: 1569-81.

45 Smeeth L, Haines A, Ebrahim S. Numbers needed to treat derived from meta-analyses - sometimes informative, usually misleading. BMJ 1999; 318: 1548-51.

46 Heit JA, Silverstein MD, Mohr DN, Petterson TM, Lohse CM, O'Fallon WM, et al. The epidemiology of venous thromboembolism in the community. Thromb Haemost 2001; 86: 452-63. [section 2] [section 3] [section 8]

47 Anderson FA Jr, Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan NA, Jovanovic B, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 1991; 151: 933-8. [section 2] [section 8]

48 Nordstrom M, Lindblad B, Bergqvist D, Kjellstrom T. A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Intern Med 1992; 232: 155-60. [section 2] [section 8]

49 Kniffin WD Jr, Baron JA, Barrett J, Birkmeyer JD, Anderson FA Jr. The epidemiology of diagnosed pulmonary embolism and deep vein thrombosis in the elderly. Arch Intern Med 1994; 154: 861-6. [section 2] [section 8]

50 Lowe GD, Osborne DH, McArdle BM, Smith A, Carter DC, Forbes CD, et al. Prediction and selective prophylaxis of venous thrombosis in elective gastrointestinal surgery. Lancet 1982; 1: 409-12.

51 Lowe GD, Haverkate F, Thompson SG, Turner RM, Bertina RM, Turpie AG, et al. Prediction of deep vein thrombosis after elective hip replacement surgery by preoperative clinical and haemostatic variables: the ECAT DVT Study. European Concerted Action on Thrombosis. Thromb Haemost 1999; 81: 879-86. [section 2] [section 3]

52 Lowe GD, Rumley A, Woodward M, Morrison CE, Philippou H, Lane DA, et al. Epidemiology of coagulation factors, inhibitors and activation markers: the Third Glasgow MONICA Survey. I. Illustrative reference ranges by age, sex and hormone use. Br J Haematol 1997; 97: 775-84.

53 Lowe GD, Rumley A, Woodward M, Reid E, Rumley J. Activated protein C resistance and the FV:R506Q mutation in a random population sample - associations with cardiovascular risk factors and coagulation variables. Thromb Haemost 1999; 81: 918-24.

54 Goldhaber SZ, Savage DD, Garrison RJ, Castelli WP, Kannel WB, McNamara PM, et al. Risk factors for pulmonary embolism. The Framingham Study. Am J Med 1983; 74: 1023-8.

55 Goldhaber SZ, Grodstein F, Stampfer MJ, Manson JE, Colditz GA, Speizer FE, et al. A prospective study of risk factors for pulmonary embolism in women. JAMA 1997; 277: 642-5.

56 Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996; 348: 977-80.

57 Campbell B. Thrombosis, phlebitis, and varicose veins. BMJ 1996; 312: 198-9. [section 2] [section 6]

58 Lane DA, Mannucci PM, Bauer KA, Bertina RM, Bochkov NP, Boulyjenkov V, et al. Inherited thrombophilia: Part 2. Thromb Haemost 1996; 76: 824-34.

59 van Beek EJ, Buller HR, ten Cate JW. Epidemiology of venous thromboembolism. In: Tooke JE, Lowe GD, editors. A textbook of vascular medicine. London: Arnold; 1996. p. 465-78. [section 2] [section 3]

60 Davies JA. Pathology and pathogenesis of venous thromboembolism. In: Tooke JE, Lowe GD, editors. A textbook of vascular medicine. London: Arnold; 1996. p. 489-504.

61 Investigation and management of heritable thrombophilia. Br J Haematol 2001; 114: 512-28. [section 2] [section 9.3] [section 9.3.1] [section 9.3.2] [section 9.3.3] [section 10]

62 Greaves M, Baglin T. Laboratory testing for heritable thrombophilia: impact on clinical management of thrombotic disease (annotation). Br J Haematol 2000; 109: 699-703.

63 Pritchard KI, Paterson AH, Paul NA, Zee B, Fine S, Pater J. Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group. J Clin Oncol 1996; 14: 2731-7.

64 Fisher B, Dignam J, Wolmark N, Wickerham DL, Fisher ER, Mamounas E, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 1999; 353: 1993-2000.

65 Rodgers A, Walker N, Schug S, McKee A, Kehlet H, van Zudert A, et al. Reduction of postoperative mortality and morbidity with epidural or spinal anaesthesia: results from overview of randomised trials. BMJ 2000; 321: 1493. [section 2] [section 7]

66 Allen C, Glasziou P, Del Mar C. Bed rest: a potentially harmful treatment needing more careful evaluation. Lancet 1999; 354: 1229-33. [section 3] [section 8]

67 Lowe GDO. Blood rheology and venous thrombosis. Clin Hemorheol 1984; 4: 571-88.

68 Vara-Thorbeck R, Rosell J. Invited commentary. World J Surg 1988; 12: 353-5.

69 Asplund K, Israelsson K, Schampi I. Haemodilution for acute ischaemic stroke (Cochrane Review). In: The Cochrane Library, Issue 3, 2001. Oxford: Update Software.

70 Pearson TC. Rheology of the absolute polycythaemias. Baillieres Clin Haematol 1987; 1: 637-64.

71 Kay TW, Martin FI. Heel ulcers in patients with long-standing diabetes who wear antiembolism stockings. Med J Aust 1986; 145: 290-1.

72 Amaragiri SV, Lees TA. Elastic compression stockings for prevention of deep vein thrombosis (Cochrane Review). In: The Cochrane Library, Issue 3, 2001. Oxford: Update software. [section 3.2] [section 3.2.1] [section 3.2.2] [section 4] [section 8.1.4] [section 8.2.2]

73 Wells PS, Lensing AW, Hirsh J. Graduated compression stockings in the prevention of postoperative venous thromboembolism. A meta-analysis. Arch Intern Med 1994; 154: 67-72. [section 3] [section 8.1.4] [section 8.2.2]

74 Wilkins RW, Mixter G, Stanton JR, Litter J. Elastic stockings in the prevention of pulmonary embolism: a preliminary report. N Engl J Med 1952; 246: 360-4.

75 Wilkins RW, Stanton JR. Elastic stockings in the prevention of pulmonary embolism II. A progress report. N Engl J Med 1953; 248: 1087-90.

76 Hui AC, Heras-Palou C, Dunn I, Triffitt PD, Crozier A, Imeson J, et al. Graded compression stockings for prevention of deep-vein thrombosis after hip and knee replacement. J Bone Joint Surg Br 1996; 78: 550-4.

77 Williams JT, Palfrey SM. Cost effectiveness and efficacy of below knee against above knee graduated compression stockings in the prevention of deep vein thrombosis. Phlebologie 1988; 41: 809-11.

78 Porteus MJ, Nicholson EA, Morris LT, James R, Negus D. Thigh length versus knee length stockings in the prevention of deep vein thrombosis. Br J Surg 1989; 76: 296-7.

79 Kalodiki E, Nicolaides AN. Graded compression stockings for the prevention of deep-vein thrombosis. J Bone Joint Surg Br 1997; 79: 507-8.

80 Francis RM, Brenkel IJ. Survey of use of thromboprophylaxis for routine hip replacement by British orthopaedic surgeons. Br J Hosp Med 1997; 57: 427-31. [section 3.2.2] [section 3.8] [section 3.9] [section 5]

81 Comerota AJ, Chouhan V, Harada RN, Sun L, Hosking J, Veermansunemi R, et al. The fibrinolytic effects of intermittent pneumatic compression: mechanism of enhanced fibrinolysis. Ann Surg 1997; 226: 306-13.

82 White RH, Gettner S, Newman JM, Trauner KB, Romano PS. Predictors of rehospitalisation for symptomatic venous thromboembolism after total hip arthroplasty. N Engl J Med 2000; 343: 1758-64.

83 Ramos R, Salem BI, De Pawlikowski MP, Coordes C, Eisenberg S, Leidenfrost R. The efficacy of pneumatic compression stockings in the prevention of pulmonary embolism after cardiac surgery. Chest 1996; 109: 82-5. [section 3] [section 4] [section 6]

84 Handoll HHG, Farrar MJ, McBirnie J, Tytherleigh-Strong G, Awal KA, Milne AA, Gillespie WG. Heparin, low molecular weight heparin and physical methods for preventing deep vein thrombosis and pulmonary embolism following surgery for hip fractures (Cochrane Review). In: The Cochrane Library, Issue 3, 2001. Oxford: Update Software. [section 3] [section 5.2.1] [section 5.2.3]

85 Gardner AM, Fox RH. The venous pump of the human foot - preliminary report. Bristol Med Chir J 1983; 98: 109-12.

86 Bradley JG, Krugener GH, Jager HJ. The effectiveness of intermittent plantar venous compression in prevention of deep venous thrombosis after total hip arthroplasty. J Arthroplasty 1993; 8: 57-61. [section 3] [section 5]

87 Fordyce MJ, Ling RS. A venous foot pump reduces thrombosis after hip replacement. J Bone Joint Surg Br 1992; 74: 45-9. [section 3] [section 5]

88 Stannard JP, Harris RM, Bucknell AL, Cossi A, Ward J, Arrington ED. Prophylaxis of deep venous thrombosis after total hip arthroplasty by using intermittent compression of the plantar venous plexus. Am J Orthop 1996; 25: 127-34. [section 3] [section 5]

89 Westrich GH, Sculco TP. Prophylaxis against deep venous thrombosis after total knee arthroplasty. Pneumatic plantar compression and aspirin compared with aspirin alone. J Bone Joint Surg Am 1996; 78: 826-34. [section 3] [section 5]

90 Santori FS, Vitullo A, Stopponi M, Santori N, Ghera S. Prophylaxis against deep-vein thrombosis in total hip replacement. Comparison of heparin and foot impulse pump. J Bone Joint Surg 1994: 76: 579-83. [section 3] [section 5]

91 Wilson NV, Das SK, Kakkar VV, Maurice HD, Smibert JG, Thomas EM, et al. Thrombo-embolic prophylaxis in total knee replacement. Evaluation of the A-V Impulse System. J Bone Joint Surg 1992; 74: 50-2. [section 3] [section 5]

92 Blanchard J, Meuwly JY, Leyvraz PF, Miron MJ, Bounameaux H, Hoffmeyer P, et al. Prevention of deep-vein thrombosis after knee replacement. Randomised comparison between a low-molecular-weight heparin (nadroparin) and mechanical prophylaxis with a foot-pump system. J Bone Joint Surg Br 1999; 81: 654-9. [section 3] [section 5]

93 Warwick D, Harrison J, Glew D, Mitchelmore A, Peters TJ, Donovan J. Comparison of the use of a foot pump with the use of low-molecular-weight heparin for the prevention of deep-vein thrombosis after total hip replacement. A prospective, randomized trial. J Bone Joint Surg Am 1998; 80: 1158-66. [section 3] [section 5]

94 British Medical Association. Royal Pharmaceutical Society of Great Britain. British National Formulary 42. London: The Association, The Society; 2001. [cited 22 Apr 2002]. Available from url: http://www.bnf.org [section 3.4] [section 3.4.5] [section 3.4.7] [section 3.5] [section 4] [section 13.3]

95 Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997; 337: 688-98.

96 Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R, et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001; 119 Suppl 1: 64S-94S. [section 3.4] [section 3.4.4] [section 3.4.5] [section 3.4.6] [section 3.4.7] [section 3.5] [section 3.6]

97 Fareed J, Haas S, Sasahar A. Past, present and future considerations on low molecular weight heparin differentiation: an epilogue. Semin Thromb Hemost 1999; 25 Suppl 3: 145-7. [section 3] [section 4]

98 Koch A, Bouges S, Ziegler S, Dinkel H, Daures JP, Victor N. Low molecular weight heparin and unfractionated heparin in thrombosis prophylaxis after major surgical intervention: update of previous meta analyses. Br J Surg 1997: 84: 750-9. [table 5] [section 3.4.2] [section 4] [section 6]

99 Koch A, Ziegler S, Breitschwerdt H, Victor N. Low molecular weight heparin and unfractionated heparin in thrombosis prophylaxis; meta-analysis based on original patient data. Thromb Res 2001; 102: 295-309. [table 5] [section 3.4.2] [section 4] [section 6]

100 Boneu B. Low molecular weight heparin therapy: is monitoring needed? Thromb Haemost 1994; 72: 330-4.

101 Monreal M, Lafoz E, Olive A, del Rio L, Vedia C. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thromb Haemost 1994; 71: 7-11.

102 Berqvist D, Breddin K, Ten Cate JW, Davidson JF, Haas S, Leyvraz PF et al. Thromboprophylaxis in hip fracture surgery: A pilot study comparing danaparoid, enoxaparin and dalteparin. Haemostasis 1999; 29: 310-7.

103 Chong BH, Gallus AS, Cade JF, Magnani H, Manoharan A, Oldmeadow M, et al. Prospective randomised open-label comparison of danaparoid with dextran 70 in the treatment of heparin-induced thrombocytopaenia with thrombosis: a clinical outcome study. Thromb Haemost 2001; 86: 1170-5.

104 Eriksson BI, Ekman S, Lindbratt B, Baur M, Bach D, Torholm C, et al. Prevention of thromboembolism with the use of recombinant hirudin. Results of a double-blind, multicenter trial comparing the efficacy of desirudin (Revasc) with that of unfractioned heparin in patients having total hip replacement. J Bone Joint Surg Am 1997; 79: 326-33.

105 Eriksson BI, Ekman S, Kalebo P, Zachrisson B, Bach D, Close P. Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393. Lancet 1996; 347: 635-9.

106 Eriksson BI, Wille-Jorgensen P, Kalebo P, Mouret P, Rosencher N, Bosch P, et al. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med 1997; 337: 1329-35.

107 Bounameaux H, Perneger T. Fondaparinux: a new synthetic pentasaccharide for thrombosis prevention. Lancet 2002; 359: 1710-1.

108 Imperiale TF, Speroff T. A meta-analysis of methods to prevent venous thromboembolism following total hip replacement. JAMA 1994;
271: 1780-5. [section 3.8] [section 3.9]

109 Barbier P, Jonville AP, Autret E, Coureau C. Fetal risks with dextrans during delivery. Drug Saf 1992; 7: 71-3.

110 Clagett GP, Reisch JS. Prevention of venous thromboembolism in general surgical patients. Results of meta-analysis. Ann Surg 1988; 208: 227-40. [section 4.1] [section 4.2.1] [section 4.2.2]

111 Haas SK, Wolf H, Ericke A, Fareed J. Prevention of fatal postoperative pulmonary embolism by low molecular weight heparin - a double blind comparison of certoparin and unfractionated heparin. Thromb Haemost 1999; 82 Suppl: 491.

112 Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330-5.

113 Salvati EA, Pellegrini VD Jr, Sharrock NE, Lotke PA, Murray DW, Potter H, et al. Recent advances in venous thromboembolic prophylaxis during and after total hip replacement. J Bone Joint Surg Am 2000; 82: 252-70. [section 5] [section 5.1] [section 5.1.1] [section 5.1.3] [section 5.1.4]

114 Gillespie W, Murray D, Gregg PJ, Warwick D. Prophylaxis against deep vein thrombosis following total hip replacement: risks and benefits of prophylaxis against venous thromboembolism in orthopaedic surgery. J Bone Joint Surg Br 2000; 82: 475-9. [section 5.1] [table 6] [section 5.1.3] [section 5.2] [section 5.2.3]

115 Warwick DJ, Whitehouse S. Symptomatic venous thromboembolism after total knee replacement. J Bone Joint Surg Br 1997; 79: 780-6.

116 Ansari S, Warwick D, Ackroyd CE, Newman JH. Incidence of fatal pulmonary embolism after 1,390 knee arthroplasties without routine prophylactic anticoagulation, except in high-risk cases. J Arthroplasty 1997; 12: 599-602.

117 Lotke PA, Palevsky H, Keenan AM, Meranze S, Steinberg ME, Ecker ML, et al. Aspirin and warfarin for thromboembolic disease after total joint arthroplasty. Clin Orthop 1996; 324: 251-8.

118 Sarmiento A, Goswami AD. Thromboembolic prophylaxis with use of aspirin, exercise, and graded elastic stockings or intermittent compression devices in patients managed with total hip arthroplasty. J Bone Joint Surg Am 1999; 81: 339-46. [section 5.1.2] [section 5.1.3]

119 Cohen AT, Bailey CS, Alikhan R, Cooper DJ. Extended thromboprophylaxis with low molecular weight heparin reduces symptomatic venous thromboembolism following lower limb arthroplasty - a meta-analysis. Thromb Haemost 2001; 85: 940-1.

120 Scottish Intercollegiate Guidelines Network (SIGN). Prevention and management of hip fracture in older people. Edinburgh: SIGN; 2002. (SIGN publication no. 56). [cited 5 Sep 2002]. Available from url: http://www.sign.ac.uk/guidelines/fulltext/56/index.html

121 Hefley FG Jr, Nelson CL, Puskarich-May CL. Effect of delayed admission to the hospital on the preoperative prevalence of deep-vein thrombosis associated with fractures about the hip. J Bone Joint Surg Am 1996; 78: 581-3.

122 Todd CJ, Freeman CJ, Camilleri-Ferrante C, Palmer CR, Hyder A, Laxton CE, et al. Differences in mortality after fracture of hip: the east Anglian audit. BMJ 1995; 310: 904-8.

123 Williams JS Jr, Hulstyn MJ, Fadale PD, Lindy PB, Ehrlich MG, Cronan J, et al. Incidence of deep vein thrombosis after arthroscopic knee surgery: a prospective study. Arthroscopy 1995; 11: 701-5.

124 Jaureguito JW, Greenwald AE, Wilcox JF, Paulos LE, Rosenberg TD. The incidence of deep venous thrombosis after arthroscopic knee surgery. Am J Sports Med 1999; 27: 707-10.

125 Schippinger G, Wirnsberger GH, Obernosterer A, Babinski K. Thromboembolic complications after arthroscopic knee surgery. Incidence and risk factors in 101 patients. Acta Orthop Scand 1998; 69: 144-6. [section 1] [section 5]

126 Demers C, Marcoux S, Ginsberg JS, Laroche F, Cloutier R, Poulin J. Incidence of venographically proved deep vein thrombosis after knee arthroscopy. Arch Intern Med 1998; 158: 47-50.

127 Upchurch GR Jr, Demling RH, Davies J, Gates JD, Knox JB. Efficacy of subcutaneous heparin in prevention of venous thromboembolic events in trauma patients. Am Surg 1995; 61: 749-55.

128 Geerts WH, Code KI, Jay RM, Chen E, Szalai JP. A prospective study of venous thromboembolism after major trauma. N Engl J Med 1994; 331: 1601-6.

129 Geerts WH, Jay RM, Code KI, Chen E, Szalai, Saibil EA, et al. A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma. N Engl J Med 1996;
335: 701-7.

130 Knudson MM, Collins JA, Goodman SB, McCrory DW. Thromboembolism following multiple trauma. J Trauma 1992; 32: 2-11.

131 Knudson MM, Morabito D, Paiement GD, Shackleford S. Use of low molecular weight heparin in preventing thromboembolism in trauma patients. J Trauma 1996; 41: 446-59.

132 Kujath P, Spannagel U, Habscheid W. Incidence and prophylaxis of deep venous thrombosis in outpatients with injury of the lower limb. Haemostasis 1993; 23 Suppl 1: 20-6.

133 Kock HJ, Schmit-Neuerburg KP, Hanke J, Rudofsky G, Hirche H. Thrombophrophylaxis with low-molecular-weight heparin in outpatients with plaster-cast immobilisation of the leg. Lancet 1995; 346: 459-61.

134 Neal DE. The National Prostatectomy Audit. Br J Urol 1997; 79 Suppl 2: 69-75.

135 Wilson RG, Smith D, Paton G, Gollock JM, Bremner DN. Prophylactic subcutaneous heparin does not increase operative blood loss in transurethral resection of the prostate. Br J Urol 1988; 62: 246-8.

136 Agnelli G. Prevention of venous thromboembolism after neurosurgery. Thromb Haemost 1999; 82: 925-30.

137 Iorio A, Agnelli G. Low-molecular-weight and unfractionated heparin for prevention of venous thromboembolism in neurosurgery: a meta-analysis. Arch Intern Med 2000; 160: 2327-32.

138 Belch JJ, Lowe GD, Pollock JG, Forbes CD, Prentice CR. Low dose heparin in the prevention of deep-vein thrombosis after aortic bifurcation graft surgery. Thromb Haemost 1980; 42: 1429-33.

139 European Working Group on Critical Leg Ischemia. Second European Consensus document on chronic critical leg ischemia. Circulation 1991; 84 Suppl 4: 1-26.

140 Libertiny G, Hands L. Deep venous thrombosis in peripheral vascular disease. Br J Surg 1999; 86: 907-10.

141 Lindberg F, Bergqvist D, Rasmussen I. Incidence of thromboembolic complications after laparoscopic cholecystectomy: review of the literature. Surg Laparosc Endosc 1997; 7: 324-31.

142 Caprini JA, Arcelus JI, Laubach M, Size G, Hoffman KN, Coats RW, et al. Postoperative hypercoagulability and deep-vein thrombosis after laparoscopic cholecystectomy. Surg Endosc 1995; 9: 304-9.

143 Bradbury AW, Chan YC, Darzi A, Stansby G. Thromboembolism prophylaxis during laparoscopic cholecystectomy. Br J Surg 1997: 84: 962-4.

144 Ah-See KW, Kerr J, Sim DW. Prophylaxis for venous thromboembolism in head and neck surgery: the practice of otolaryngologists. J Laryngol Otol 1997; 111: 845-9.

145 Scottish arthroplasty project. [cited 5 Sep 2002]. Available from url: http://www.show.scot.nhs.uk/isd/clinical_gov/nat_inf_sources/nat_inf_sources.htm#arthro

146 Holtas S, Heiling M, Lonntoft M. Spontaneous spinal epidural haematoma: findings at MR imaging and clinical correlation. Radiology 1996; 199: 409-13.

147 Groen RJ, Ponssen H. The spontaneous spinal epidural hematoma. A study of the etiology. J Neurol Sci 1990; 98: 121-38.

148 Vandermeulen EP, Van Aken H, Vermylen J. Anticoagulants and spinal-epidural anesthesia. Anesth Analg 1994; 79: 1165-77.

149 Wysowski DK, Talarico L, Bacsanyi J, Botstein P. Spinal and epidural hematoma and low-molecular-weight heparin. N Engl J Med 1998; 338: 1774-5. [section 7.2] [section 7.2.4]

150 Wildsmith JA, McClure JH. Anticoagulant drugs and central nerve blockade. Anaesthesia 1991; 46: 613-4. [section 7.2] [section 7.2.2]

151 Tryba M, Wedel DJ. Central neuraxial block and low molecular weight heparin (enoxaparine): lessons learned from different dosage regimens in two continents. Acta Anaesthesiol Scand Suppl 1997; 111: 100-4.

152 Checketts MR, Wildsmith JA. Central nerve block and thromboprophylaxis - is there a problem? Br J Anaesth 1999; 82: 164-7.

153 Odoom JA, Sih IL. Epidural analgesia and anticoagulant therapy. Experience with one thousand cases of continuous epidurals. Anaesthesia 1983; 38: 254-9.

154 Wu CL, Perkins FM. Oral anticoagulant prophylaxis and epidural catheter removal. Reg Anesth 1996; 21: 517-24.

155 Horlocker TT, Wedel DJ, Schlichting JL. Postoperative epidural analgesia and oral anticoagulant therapy. Anesth Analg 1994; 79: 89-93.

156 Kearon C, Hirsh J. Management of anticoagulation before and after elective surgery. N Engl J Med 1997; 336: 1506-11.

157 Scottish Intercollegiate Guidelines Network (SIGN). Perioperative blood transfusion for elective surgery. Edinburgh: SIGN; 2001. (SIGN publication no. 54). [cited 5 Sep 2002]. Available from url: http://www.sign.ac.uk/guidelines/fulltext/54/index.html

158 Schwander D, Bachmann F. [Heparin and spinal or epidural anesthesia: decision analysis] French. Ann Fr Anesth Reanim 1991; 10: 284-96.

159 Cooke ED, Lloyd MJ, Bowcock SA, Pilcher MF. Monitoring during low-dose heparin prophylaxis [letter]. N Engl J Med 1976; 294: 1066-7.

160 Horlocker TT, Wedel DJ. Anticoagulation and neuraxial block: historical perspective, anesthetic implications, and risk management. Reg Anesth Pain Med 1998;23 Suppl 2: 129-34. [section 7.2.3] [section 7.2.4] [section 8]

161 Gubitz G, Counsell C, Sandercock P, Signorini D. Anticoagulants for acute ischaemic stroke (Cochrane Review). In: The Cochrane Library, Issue 3, 2001. Oxford: Update Software. [section 8] [section 8.2.4]

162 Counsell C, Sandercock P. Low-molecular-weight heparins or heparinoids versus standard unfractionated heparin for acute ischaemic stroke (Cochrane Review). In: The Cochrane Library, Issue 3, 2001. Oxford: Update Software.

163 Cairns JA, Hirsh J, Lewis HD Jr, Resnekov L, Theroux P. Antithrombotic agents in coronary artery disease. Chest 1992; 102 Suppl 4: 456S-81S.

164 Kierkegaard A, Norgren L. Graduated compression stockings in the prevention of deep vein thrombosis in patients with acute myocardial infarction. Eur Heart J 1993; 14: 1365-8. [section 8.1.4] [section 8.3.2]

165 Kelly J, Rudd A, Lewis R, Hunt BJ. Venous thromboembolism after acute stroke. Stroke 2001; 32: 262-7.

166 Scottish Intercollegiate Guidelines Network (SIGN). Management of patients with stroke part IV: rehabilitation, prevention and management of complications, and discharge planning. Edinburgh: SIGN; 1998. (SIGN publication no. 24). [cited 5 Sep 2002]. Available from url: http://www.sign.ac.uk/pdf/sign24.pdf

167 Indredavik B, Bakke F, Slordahl SA, Rokseth R, Haheim LL. Treatment in a combined acute and rehabilitation stroke unit: which aspects are most important? Stroke 1999; 30: 917-23.

168 Langhorne P, Tong BL, Stott DJ. Association between physiological homeostasis and early recovery after stroke. Stroke 2000; 31: 2518-9.

169 Asplund K, Israelsson K, Schampi I. Haemodilution for acute ischaemic stroke (Cochrane Review). In: The Cochrane Library, Issue 1, 2001. Oxford: Update Software.

170 Mazzone C, Chiodo Grande F, Sandercock P, Miccio M, Salvi R. Physical methods for preventing deep vein thrombosis in stroke. (Cochrane Review). In: The Cochrane Library, Issue 3, 2001. Oxford: Update Software.

171 Turpie AG, Hirsh J, Gent M, Julian D, Johnson J. Prevention of deep vein thrombosis in potential neurosurgical patients. A randomized trial comparing graduated compression stockings alone or graduated compression stockings plus intermittent pneumatic compression with control. Arch Intern Med 1989; 149: 679-81.

172 Gubitz G, Sandercock P, Counsell C. Antiplatelet therapy for acute ischaemic stroke (Cochrane Review). In: The Cochrane Library, Issue 3, 2001. Oxford: Update Software. [section 8.2.3] [section 8.2.4]

173 Bath PM, Lindenstrom E, Boysen G, De Deyn P, Friis P, Leys D, et al. Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial. Lancet 2001; 358: 702-10.

174 Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbon C, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 1999; 341: 793-800.

175 Zornberg GL, Jick H. Antipsychotic drug use and risk of first-time idiopathic venous thromboembolism: a case-control study. Lancet 2000; 356: 1219-23.

176 Tapson VF. Risk of venous thromboembolism with use of antipsychotic drugs. Lancet 2000; 356: 1206.

177 Greer IA. Thrombosis in pregnancy: maternal and fetal issues. Lancet 1999; 353: 1258-65. [section 9] [section 9.1]

178 Ginsberg JS, Greer I, Hirsh J. Use of antithrombotic agents during pregnancy. Chest 2001; 119 Suppl 1: 122S-131S. [section 9] [section 9.2] [section 9.4]

179 McColl MD, Ramsay JE, Tait RC, Walker ID, McCall F, Conkie JA, et al. Risk factors for pregnancy associated venous thromboembolism. Thromb Haemost 1997; 78: 1183-8.

180 Schulman S, Hellgren-Wangdahl M. Pregnancy, heparin and osteoporosis. Thromb Haemost 2002; 87: 180-1.

181 Pettila V, Leinonen P, Markkola A, Hiilesmaa V, Kaaja R. Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. Thromb Haemost 2002; 87: 182-6.

182 Lepercq J, Conard J, Borel-Derlon A, Darmon JY, Boudignat O, Francoual C, et al. Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies. BJOG 2001; 108: 1134-40.

183 Sanson BJ, Lensing AW, Prins MH, Ginsberg J S, Barkagan Z S, Lavenne-Pardonge E, et al. Safety of low-molecular-weight heparin in pregnancy: a systematic review. Thromb Haemost 1999; 81: 668-72.

184 Gerhardt A, Scharf RE, Beckmann MW, Struve S, Bender HG, Pillny M, et al. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. N Engl J Med 2000; 342: 374-80.

185 McColl MD, Ellison J, Reid F, Tait RC, Walker ID, Greer IA. Prothrombin 20210 G—>A, MTHFR C677T mutations in women with venous thromboembolism associated with pregnancy. BJOG 2000; 107: 565-9.

186 Eldor A. Thrombophilia, thrombosis and pregnancy. Thromb Haemost 2001; 86: 104-11.

187 Brill-Edwards P, Ginsberg JS, Gent M, Hirsh J, Burrows R, Kearon C, et al. Safety of withholding heparin in pregnant women with a history of venous thromboembolism. Recurrence of Clot in This Pregnancy Study Group. N Engl J Med 2000; 343: 1439-44. [section 9.2] [section 9.4]

188 Herrada J, Noble LS, Kutteh WE. Safety of the treatment of antiphospholipid syndrome associated with recurrent pregnancy loss with enoxaparin and low dose aspirin. Blood 2000; 96: 4100.

189 Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ 1997; 314: 253-7.

190 Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995; 346: 1589-93.

191 Rosendaal F, Helmerhorst FM, Vandenbroucke JP. Oral contraceptives, hormone replacement therapy and thrombosis. Thromb Haemost 2001; 86: 112-23.

192 Vandenbrouke JP, Bloemenkamp KW, Rosendaal FR, Helmerhorst FM. Incidence of venous thromboembolism in users of combined oral contraceptives. Risk is particularly high with first use of oral contraceptives. BMJ 2000; 320: 57-8.

193 Vessey MP, Doll R, Fairbairn AS, Glober G. Postoperative thromboembolism and the use of oral contraceptives. Br Med J 1970; 3: 123-6.

194 Poulter NR, Chang CL, Farley TM, Meirik O. Risk of cardiovascular diseases associated with oral progestagen preparations with therapeutic indications. Lancet 1999; 354:1610.

195 Vasilakis C, Jick H, del Mar Melero-Montes M. Risk of idiopathic venous thromboembolism in users of progestagens alone. Lancet 1999;
354: 1610-1.

196 Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomised clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999; 282: 637-45.

197 Lowe G, Woodward M, Vessey M, Rumley A, Gough P, Daly E. Thrombotic variables and risk of idiopathic venous thromboembolism in women aged 45-64 years. Relationships to hormone replacement therapy. Thromb Haemost 2000; 83: 530-5.

198 Rosendaal FR, Vessey M, Rumley A, Daly E, Woodward M, Helmerhorst FM, et al. Hormonal replacement therapy, prothrombotic mutations and the risk of venous thrombosis. Br J Haematol 2001; 116: 851-4.

199 Grady D, Wenger NK, Herrington D, Khan S, Furberg C, Hunninghake D, et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study. Ann Intern Med 2000; 132: 689-96.

200 Hoibratten E, Qvigstad E, Arnesen H, Larsen S, Wickstrom E, Sandset PM. Increased risk of recurrent venous thromboembolism during hormone replacement therapy - results of the randomized, double-blind, placebocontrolled estrogen in venous thromboembolism trial (EVTET). Thromb Haemost 2000; 84: 961-7.

201 New product information for hormone replacement therapy. Curr Probl Pharmacovigilance 2002; 28: 1-2. [cited 5 Sep 2002]. Available from url: http://www.mca.gov.uk/ourwork/monitorsafequalmed/currentproblems/cpapril2002.pdf

202 Lowe GD, Upton MN, Rumley A, McConnachie A, OíReilly DS, Watt GC. Different effects of oral and transdermal hormone replacement therapies on factor IX, APC resistance, t-PA, PAI and C-reactive protein - a cross-sectional population survey. Thromb Haemost 2001; 86: 550-6.

203 Ferrari E, Chevallier T, Chapelier A, Baudouy M. Travel as a risk factor for venous thromboembolic disease: a case-control study. Chest 1999; 115: 440-4.

204 Samama MM. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med 2000; 160: 3415-20.

205 Ten Wolde M, Quak E, Prims MH, Kraaijenhogen RA, Buller HR. Long distance travelling increases risk of pulmonary embolism.Thromb Haemost 2001; 86: Suppl.

206 MacGillavry MR, Glas AS, Bossuyt PM, Prins MH. Fright of flight-related venous thromboembolism: evidence or emotion based? Thromb Haemost 2001; 86: 1336-8.

207 Hirsh J, O'Donnell MJ. Venous thromboembolism after long flights: are airlines to blame? Lancet 2001; 357: 1461-2.

208 Kraaijenhagen RA, Haverkamp P, Koopman MM, Prandoni P, Piovella F, Buller HR. Travel and risk of venous thrombosis. Lancet 2000; 356: 1492-3.

209 Arya R, Barnes JA, Hossain U, Patel RK, Cohen AT. Long-haul flights and deep vein thrombosis: a significant risk only when additional factors are also present. Br J Haematol 2002; 116: 653-4.

210 Ansell JE. Air travel and venous thromboembolism - is the evidence in? N Engl J Med 2001; 345: 828-9.

211 Lapostolle F, Surget V, Borron SW, Desmaizieres M, Sordelet D, Lapandry C, et al. Severe pulmonary embolism associated with air travel. N Engl J Med 2001; 345: 828-9.

212 Cesarone MR, Belcaro G, Nicolaides AN, Incandela L, De Sanctis MT, Geroulakos G et al. Venous thrombosis from air travel; the LONFLIT3 Study. Prevention with aspirin vs. low molecular weight heparin in high risk subjects: a randomised trial. Angiology 2002; 53:1-6.

213 Giangrande PLF. Air travel and thrombosis: is there a link? Br J Haemat 2002; 117: 509-12.

214 Scurr JH, Machin SJ, Bailey-King S, Mackie IJ, McDonald S, Smith PD. Frequency and prevention of symptomless deep -vein thrombosis in long-haul flights: a randomised trial. Lancet 2001; 357:1485-9.